Thousands of Aussie women to benefit from cheaper medicine in May

A new treatment for a common painful condition, along with two other drugs, will soon become far more affordable, improving the lives of thousands of Australian women.

The federal government announced on Sunday that, from May 1, about 8,500 Australian women are expected to benefit annually from the inclusion of Ryeqo on the Pharmaceutical Benefits Scheme (PBS). The drug offers a new treatment option for endometriosis sufferers who experience moderate to severe pain and have not found relief through other hormonal treatments and painkillers.

Endometriosis affects one in seven Australian women, with tissue similar to the womb’s lining growing elsewhere in the body, leading to severe pain and potential fertility issues. Symptoms can vary, often causing delays in diagnosis that average six and a half years, according to Endometriosis Australia.

Additional subsidies will also reduce the costs of a progestogen-only contraceptive pill and an IVF hormone therapy. Women with low hormone levels will now have earlier access to Pergoveris for $32 per treatment cycle from their first IVF attempt, rather than waiting for multiple failed cycles. An unsubsidised cycle typically costs around $3,500.

Adelaide mother Helana Shehadeh told 7News that she used Pergoveris during her second IVF cycle in 2023, resulting in the birth of baby Zayn. She said that it's important to get early access to fertility treatments, adding that, “Anyone who has been through IVF understands the agony of multiple cycles. Earlier access to this fertility treatment will alleviate some of the burden for women undergoing IVF.”

The announcement comes as Australia’s birth rate falls to a record low of 1.5 babies per woman. Fertility Society of Australia and New Zealand president Petra Wale welcomed the move, highlighting the financial strain of assisted reproduction. “The cost of assisted reproduction remains a major barrier for many families, particularly amid the ongoing cost-of-living crisis. Fewer financial and logistical hurdles mean more families can focus on what truly matters – having a baby,” she said.

“Women have asked government to take their health care seriously," said Health Minister Mark Butler, "and we have listened. These listings could save women and their families thousands of dollars across their lifetimes.”

Addressing criticism over delays in listing Ryeqo, Butler defended the government’s actions, stating that all recommendations had been handled “expeditiously”. He noted that in the previous nine years under the coalition government, “not a single new pill, not a single endometriosis treatment, not a single menopause treatment” was added to the PBS.

The opposition, however, criticised the government for leaving women waiting more than a year for “potentially life-changing medications”. Opposition health spokeswoman Senator Anne Ruston reaffirmed the coalition’s commitment to timely PBS listings for all Pharmaceutical Benefits Advisory Committee-recommended medicines.

Additionally, the cost of the contraceptive pill Slinda, used by about 80,000 women, will also be reduced under the PBS. The annual price will drop from approximately $320 to $94 for general patients and to $22 for concession card holders. Slinda, a progestogen-only pill, is particularly suitable for older women, smokers, women at increased risk of blood clots, and those who suffer from migraines.

Image: Shutterstock